Chronic disease patients are more compliant when Rx co-payments decrease.
Removing economic barriers to treatment for chronic conditions encourages patients to remain on recommended therapies, according to a new study published in the January/February 2008 issue of Health Affairs. The study, funded in part by GlaxoSmithKline, investigated the impact on medication adherence of reducing prescription co-paymentsin addition to existing disease management programsfor employees of a leading service industry company. "The Impact of Decreasing Co-payments on Medication Adherence in the Context of a Disease Management Program" covered a 12-month study. Co-payment rates for generic medications were reduced from $5 to $0; co-payments for branded drugs were cut in half.